Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Onglyza efficacy is competitive with other DPP-4 inhibitors, Bristol-Myers Squibb/AstraZeneca say - Partners say new data on saxagliptin efficacy, presented at EASD in Rome, show competitive profile and are preparing a head-to-head trial with Merck's Januvia. Onglyza and Takeda's alogliptin could join Januvia on the market in the next year, but it's not clear how the new drugs will be differentiated. Heightened scrutiny of diabetes drug safety could help Merck maintain an advantage

You may also be interested in...

Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor

Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)

Diabetes Therapies Need Cardiovascular Safety Data For Approval, Panel Says

Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting

Takeda’s Alogliptin Strategy: Treatment Options

With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts